J0693 — Injection, cefiderocol, 5 mg
J0693 is a HCPCS Level II code for injection, cefiderocol, 5 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on September 30, 2021 and is not valid on new claims.
This code has been terminated
CMS terminated J0693 on September 30, 2021. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J0693
- Long descriptor
- Injection, cefiderocol, 5 mg
- Short descriptor
- Inj., cefiderocol, 5 mg
- Added
- January 1, 2021
- Terminated
- September 30, 2021
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0693
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0693 is not quite right, the correct code is very often within a few positions of it.
- J0675Injection, carboprost tromethamine, 0.1 mg
- J0681Injection, ceftobiprole medocaril sodium, 3 mg
- J0687Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
- J0688Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
- J0689Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg
- J0690Injection, cefazolin sodium, 500 mg
- J0691Injection, lefamulin, 1 mg
- J0692Injection, cefepime hydrochloride, 500 mg
- J0694Injection, cefoxitin sodium, 1 gm
- J0695Injection, ceftolozane 50 mg and tazobactam 25 mg
- J0696Injection, ceftriaxone sodium, per 250 mg
- J0697Injection, sterile cefuroxime sodium, per 750 mg
- J0698Injection, cefotaxime sodium, per gm
- J0699Injection, cefiderocol, 10 mg
- J0701Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0702Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
Questions about J0693
What is HCPCS code J0693?
J0693 is a HCPCS Level II code for injection, cefiderocol, 5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0693?
The CMS HCPCS file marks J0693 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J0693 still valid?
No. J0693 was terminated on September 30, 2021 and should not be used on new claims.